GLP1R and type 2 diabetes mellitus: Dulaglutide (LY2189265; Eli Lilly and Company, USA) is a novel, long-acting GLP-1 receptor agonist that is administered via subcutaneous injection for the treatment of type 2 diabetes mellitus (T2DM), and has been approved by the United States Food and Drug Administration (FDA).